Copyright
©2009 Baishideng.
World J Hepatol. Oct 31, 2009; 1(1): 90-97
Published online Oct 31, 2009. doi: 10.4254/wjh.v1.i1.90
Published online Oct 31, 2009. doi: 10.4254/wjh.v1.i1.90
Clinical characteristics | Data |
Mean age (yr) | 51.6 (range 27-81 yr) |
Gender | |
Males | 21 |
Females | 4 |
Prior therapy | |
TACE | 6 |
Liver resection | 9 |
TACE after surgery | 8 |
TACE + RFA or PEI | 2 |
Unexplained AFP increase after treatment | 14 |
Mean time from treatment to recurrence | 11.5 mo |
Mean time after treatment to PET/CT exam | 10 d - 12 yr; mean 13 mo |
Mean follow up time after PET/CT exam | 3 mo - 21 mo; mean 12 mo |
Characteristics | n |
Intrahepatic recurrence | 8 |
Intrahepatic recurrence and extrahepatic metastases | 5 |
Extrahepatic metastases without intrahepatic recurrence | 4 |
Single intrahepatic recurrence | 7 |
Multiple intrahepatic recurrence | 8 |
Lung | 4 |
Bone | 1 |
Omentum and mesentery | 3 |
Retroperitoneal lymph nodes | 2 |
Adrenal | 1 |
- Citation: Sun L, Guan YS, Pan WM, Luo ZM, Wei JH, Zhao L, Wu H. Metabolic restaging of hepatocellular carcinoma using whole-body 18F-FDG PET/CT. World J Hepatol 2009; 1(1): 90-97
- URL: https://www.wjgnet.com/1948-5182/full/v1/i1/90.htm
- DOI: https://dx.doi.org/10.4254/wjh.v1.i1.90